Lineage Cell Therapeutics

Receive alerts
Market Cap:
$359.98 m
2.40 USD
52 weeks high
52 weeks low

In brief

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer. Lineage is also evaluating potential partnership opportunities for Renevia®, a facial aesthetics product that was recently granted a Conformité Européenne (CE) Mark.

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Four high-flying growth companies set to take the stage at Proactive's biggest virtual investor forum to date

Join KWESST, Lineage Cell Therapeutics, Killi and Algernon Pharmaceuticals at Proactive's One2One virtual investor forum on December 8 at 1:30pm ET

on 7/12/20